Bausch + Lomb, the global leader in eye health, is the owner of several eye health brands including PreserVision, PureVision, renu and VICTUS. It was estimated to generate around $3.3 billion in revenue and about $720 million in 2013 EBITDA. Thus, with around a $8.7 billion offering price, Valeant Pharmaceuticals Intl Inc (NYSE:VRX) has valued Bausch + Lomb at around 12 times its EBITDA. Valeant seems to make the right move to leverage the increasing demand in eye health, resulted from a growing demand in emerging markets, aging population and an increasing number of diabetes patients. Michael Pearson commented that with Bausch + Lomb's eye care comprehensive portfolio, it would be a great " strategic fit " with Valeant's ophthalmology business. He said: " With this transaction, Valeant will be a worldwide leader in both dermatology and eye health ."